Tucatinib plus Doxil for HER2-positive metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study tests tucatinib (a HER2-targeted pill) plus Doxil (a chemotherapy medicine) to slow or shrink HER2-positive metastatic breast cancer that has been treated before. It may help by targeting HER2 cancer cells more effectively than past treatments alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent (or your legal guardian can).
- Your breast cancer must be confirmed HER2-positive and metastatic or locally advanced, based on local lab testing.
- You have had at least one prior anti-HER2 treatment for this advanced/metastatic cancer (tucatinib before in the metastatic setting is allowed).
- Your body function must be good enough (performance status score of 0 or 1, and blood counts like neutrophils, platelets, and hemoglobin meet the study limits).
- You must have at least one measurable tumor spot on scans, and your brain MRI must meet specific brain-metastasis safety rules.
- You must not have had certain recent treatments (like chemo/targeted drugs in the last ~21 days or related washout), recent major surgery, or certain recent radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches how well a three-drug combination (tucatinib, capecitabine, and trastuzumab) works for women with breast cancer that has spread to other parts of the body and has a protein called HER2. You'll be treated as you normally would be in a clinic, and researchers will track how you respond.
This trial tests a combination of two drugs that target HER2-positive breast cancer: trastuzumab deruxtecan (currently the standard) plus a newer drug called pyrotinib. The goal is to see if combining these drugs helps people whose cancer has continued to grow despite taking trastuzumab deruxtecan alone.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests a new combination of drugs (zanidatamab, tucatinib, and chemotherapy) for people with advanced HER2-positive breast cancer that has stopped responding to previous treatments. The goal is to see if this combination can shrink tumors or slow the disease.
This study tests a combination of two targeted therapies—trastuzumab deruxtecan and pyrotinib—as a first treatment for HER2-positive breast cancer that has spread. The goal is to see if this combination helps shrink tumors or delay progression better than current options.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.